Therapeutic Asset Ratings
394 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Capecitabine
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Capecitabine
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Docetaxel
Gastric Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Docetaxel
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Docetaxel
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Eloxatin
Endometrial Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
Eloxatin
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Eloxatin
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Favezelimab
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
P2
B
(57)
FLUOROURACILUM
Endometrial Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
FLUOROURACILUM
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
FLUOROURACILUM
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
LENVATINIB
Esophageal Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
LENVATINIB
Gastric Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
LENVATINIB
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
LENVATINIB
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
mk-4830
Ovarian Serous Adenocarcinoma
Merck Sharp & Dohme LLC
P2
B
(57)
mk-4830
Ovarian Carcinoma
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Endometrial Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Esophageal Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Gallbladder Cancer
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Head And Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Gastric Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Triple-Negative Breast Carcinoma
Merck Sharp & Dohme LLC
P2
B
(57)
Pembrolizumab/Vibostolimab Coformulation
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLC
P2
B
(57)
Showing 151 to 175 of 394 assets
Previous
Page 7 of 16
Next